Voyager Therapeutics (VYGR) Cash & Current Investments (2014 - 2026)

Voyager Therapeutics has reported Cash & Current Investments for 13 years, with the latest figure at $141.5 million in Q1 2026.

• Quarterly Cash & Current Investments fell 40.06% year-over-year to $141.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $141.5 million (down 40.06% YoY) and the FY2025 annual result came in at $196.4 million, down 26.34% from the prior year.
• Cash & Current Investments declined to $141.5 million in Q1 2026 per VYGR's latest filing, from $196.4 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $399.6 million in Q1 2024 and troughed at $118.8 million in Q4 2022.
• A 5-year average of $233.9 million and a median of $230.9 million in 2023 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2025: Cash & Current Investments soared 94.26% in 2023, then tumbled 41.89% in 2025.
• Over 5 years, Cash & Current Investments stood at $118.8 million in 2022, then jumped by 94.26% to $230.9 million in 2023, then increased by 15.51% to $266.7 million in 2024, then retreated by 26.34% to $196.4 million in 2025, then slipped by 27.98% to $141.5 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $141.5 million, $196.4 million, and $208.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.